In Massachusetts, Xenetic Biosciences, Inc. has a new Chief Scientific Officer, Curtis A. Lockshin. Lockshin’s experience with research and development in the biopharmaceutical industry and his various biomaterials, therapeutics and biosensors inventions and patents will come in handy in his new role at Xenetic, a biopharmaceutical company. Lockshin was formerly a CEO, or served in other executive roles, at SciVac Therapuetics, VBI Vaccines, Guardum Pharmaceuticals, and OPKO Health. Lockshin will help Xenetic with their focus on next-gen biologic drugs and oncology therapeutics. Scott Maguire, Chief Executive Officer of Xenetic said in their press release “With our second important executive level appointment since our Nasdaq listing, Xenetic now has a structure to deliver on what we believe will be a transformational 2017.”
Latest article
Absolut Vodka inks new partnership in biodegradable bottle pursuit
In Sweden, Absolut Vodka has inked a new partnership with start-up Blue Ocean Closures to increase the use of biodegradable materials in its packaging....
“Magic” mushrooms take centerstage at Glastonbury music festival
In the United Kingdom, acoustic panels made from hemp and mycelium were used in the ceiling of a dance music tent at the recent ...
Beverage company and designer create Dirt Shoe that disintegrates in minutes
In New York, beverage company Yerba Madre and design studio Basura have partnered to create shoes out of dirt, organic fibers, and acacia gum...